Tags

Type your tag names separated by a space and hit enter

Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.
Handb Exp Pharmacol. 2015; 231:423-47.HE

Abstract

Components of the so-called endocannabinoid system, i.e., cannabinoid receptors, endocannabinoids, as well as enzymes involved in endocannabinoid synthesis and degradation, have been identified both in the gastrointestinal and in the urinary tract. Evidence suggests that the endocannabinoid system is implicated in many gastrointestinal and urinary physiological and pathophysiological processes, including epithelial cell growth, inflammation, analgesia, and motor function. A pharmacological modulation of the endocannabinoid system might be beneficial for widespread diseases such as gastrointestinal reflux disease, irritable bowel syndrome, inflammatory bowel disease, colon cancer, cystitis, and hyperactive bladder. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids, non-psychotropic cannabinoids (notably cannabidiol), and palmitoylethanolamide, an acylethanolamide co-released with the endocannabinoid anandamide, are promising candidates for gastrointestinal and urinary diseases.

Authors+Show Affiliations

Department of Pharmacy, University of Naples Federico II, Naples, Italy. aaizzo@unina.it. Endocannabinoid Research Group, Naples, Italy. aaizzo@unina.it.Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Bruxelles, Belgium.Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, USA.Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26408170

Citation

Izzo, Angelo A., et al. "Endocannabinoids and the Digestive Tract and Bladder in Health and Disease." Handbook of Experimental Pharmacology, vol. 231, 2015, pp. 423-47.
Izzo AA, Muccioli GG, Ruggieri MR, et al. Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. Handb Exp Pharmacol. 2015;231:423-47.
Izzo, A. A., Muccioli, G. G., Ruggieri, M. R., & Schicho, R. (2015). Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. Handbook of Experimental Pharmacology, 231, 423-47. https://doi.org/10.1007/978-3-319-20825-1_15
Izzo AA, et al. Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. Handb Exp Pharmacol. 2015;231:423-47. PubMed PMID: 26408170.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. AU - Izzo,Angelo A, AU - Muccioli,Giulio G, AU - Ruggieri,Michael R, AU - Schicho,Rudolf, PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2015/12/19/medline KW - 2-Arachydonoylglycerol KW - Anandamide KW - Bladder KW - Cancer KW - Cannabidiol KW - Cannabinoid receptors KW - Cystitis KW - Fatty acid amide hydrolase KW - Inflammation KW - Monoacylglycerol lipase KW - Palmitoylethanolamide KW - Transient receptor potential channels SP - 423 EP - 47 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 231 N2 - Components of the so-called endocannabinoid system, i.e., cannabinoid receptors, endocannabinoids, as well as enzymes involved in endocannabinoid synthesis and degradation, have been identified both in the gastrointestinal and in the urinary tract. Evidence suggests that the endocannabinoid system is implicated in many gastrointestinal and urinary physiological and pathophysiological processes, including epithelial cell growth, inflammation, analgesia, and motor function. A pharmacological modulation of the endocannabinoid system might be beneficial for widespread diseases such as gastrointestinal reflux disease, irritable bowel syndrome, inflammatory bowel disease, colon cancer, cystitis, and hyperactive bladder. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids, non-psychotropic cannabinoids (notably cannabidiol), and palmitoylethanolamide, an acylethanolamide co-released with the endocannabinoid anandamide, are promising candidates for gastrointestinal and urinary diseases. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/26408170/Endocannabinoids_and_the_Digestive_Tract_and_Bladder_in_Health_and_Disease_ L2 - https://dx.doi.org/10.1007/978-3-319-20825-1_15 DB - PRIME DP - Unbound Medicine ER -